http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020123699-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1721d75f5bf603447ec5a26b5c1c0be0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2019-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd595384145ffdb796e7cca2fd771574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2740d29ffe05bea54c84dc3b04fdc216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89a35547fdeacc4cdca775c9dd1f161f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8bdb6f750c2825446a99edaaa185033 |
| publicationDate | 2020-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020123699-A1 |
| titleOfInvention | Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof |
| abstract | The present disclosure provides, inter alia, scaffolds and compounds having the structure (I). Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of a cancer in a subject, methods for selectively killing a cancer cell, methods of modulating mTORC1/2 signaling activity in a cell, methods of modulating the activity of a Master Regulator for MycN in a subject having MycN-amplified neuroblastoma (MycN AMP NBL), methods of selectively treating or ameliorating effects of a cancer in a subject in need thereof, and platforms and methods for identifying a compound that induces degradation of a cancer-related protein. Also provided are kits comprising a compound or a pharmaceutical composition according to the present disclosure. Methods for treating cancers and methods for modulating MYC Master Regulators using other compounds are also provided. |
| priorityDate | 2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 267.